(Q53480856)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17511757%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

title

Treatment of choroidal neovascularization using intravitreal bevacizumab (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17511757%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17511757%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Michael Larsen

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17511757%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Robert Pedersen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17511757%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Henrik Lund-Andersen

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17511757%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

publication date

18 May 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17511757%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17511757%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

85

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17511757%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17511757%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

526-533

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17511757%20AND%20SRC:MED&resulttype=core&format=json

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

30 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00895.X

Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00895.X

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00895.X

Retinal pigment epithelial tear following intravitreal pegaptanib sodium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00895.X

The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00895.X

Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00895.X

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00895.X

Effects of bevacizumab on retinal function in isolated vertebrate retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00895.X

Testing intravitreal toxicity of bevacizumab (Avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00895.X

Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00895.X

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00895.X

Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00895.X

Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00895.X

Ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00895.X

Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00895.X

Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00895.X

Kinetics of retinal lipoprotein precipitation and elimination after closure of subretinal new vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00895.X

Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00895.X